Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 5
1973 4
1975 3
1976 1
1977 4
1978 3
1979 3
1980 1
1981 4
1982 1
1983 3
1984 2
1985 5
1986 3
1987 6
1988 5
1989 3
1990 7
1991 5
1992 6
1993 6
1994 11
1995 7
1996 6
1997 6
1998 7
1999 4
2000 5
2001 4
2002 6
2003 7
2004 3
2005 5
2006 9
2007 7
2008 3
2009 3
2010 6
2011 5
2012 4
2013 9
2014 9
2015 5
2016 2
2017 3
2018 1
2019 1
2020 1
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

210 results
Results by year
Filters applied: . Clear all
Page 1
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
[No authors listed] [No authors listed] Lancet. 1998 Sep 12;352(9131):837-53. Lancet. 1998. PMID: 9742976 Clinical Trial.
METHODS: 3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a mean of two fasting plasma glucose (FPG) concentrations of 6.1-15.0 mmol/L were randomly assigned intensive policy with a sulphonylurea (ch …
METHODS: 3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a …
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.
Abdul-Ghani M, Puckett C, Adams J, Khattab A, Baskoy G, Cersosimo E, Triplitt C, DeFronzo RA. Abdul-Ghani M, et al. Diabetes Care. 2021 Feb;44(2):433-439. doi: 10.2337/dc20-0978. Epub 2020 Dec 3. Diabetes Care. 2021. PMID: 33273042 Clinical Trial.
OBJECTIVE: To compare the long-term efficacy of initiating therapy with metformin/pioglitazone/exenatide in patients with new-onset type 2 diabetes mellitus (T2DM) versus sequential addition of metformin followed by glipizide and insulin. RESEARCH DESIGN AND METHODS: Drug- …
OBJECTIVE: To compare the long-term efficacy of initiating therapy with metformin/pioglitazone/exenatide in patients with new-onset type 2 d …
Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.
Gu Y, Wang X, Li J, Zhang Y, Zhong H, Liu R, Zhang D, Feng Q, Xie X, Hong J, Ren H, Liu W, Ma J, Su Q, Zhang H, Yang J, Wang X, Zhao X, Gu W, Bi Y, Peng Y, Xu X, Xia H, Li F, Xu X, Yang H, Xu G, Madsen L, Kristiansen K, Ning G, Wang W. Gu Y, et al. Nat Commun. 2017 Nov 27;8(1):1785. doi: 10.1038/s41467-017-01682-2. Nat Commun. 2017. PMID: 29176714 Free PMC article. Clinical Trial.
Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve metabolic health. Here we show that treatment with Acarbose, but not Glipizide, increases the ratio between primary BAs and secondary B …
Antidiabetic medication may modulate the gut microbiota and thereby alter plasma and faecal bile acid (BA) composition, which may improve me …
Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease.
Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G; SPREAD-DIMCAD Investigators. Hong J, et al. Diabetes Care. 2013 May;36(5):1304-11. doi: 10.2337/dc12-0719. Epub 2012 Dec 10. Diabetes Care. 2013. PMID: 23230096 Free PMC article. Clinical Trial.
RESULTS: At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in the glipizide group and 7.0% in the metformin group). At a median follow-up of 5.0 years, 91 participants had developed 103 primary en …
RESULTS: At the end of study drug administration, both groups achieved a significant decrease in the level of glycated hemoglobin (7.1% in t …
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, Parikh SJ. Nauck MA, et al. Diabetes Care. 2011 Sep;34(9):2015-22. doi: 10.2337/dc11-0606. Epub 2011 Aug 4. Diabetes Care. 2011. PMID: 21816980 Free PMC article. Clinical Trial.
We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes inadequately controlled with metformin monotherapy. ...RESULTS: The primary end point, adjusted mean HbA(1c) reduction with dapagliflozin (- …
We compared the efficacy, safety, and tolerability of dapagliflozin with the sulfonylurea glipizide in patients with type 2 diabetes …
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?
Feig DS, Briggs GG, Koren G. Feig DS, et al. Ann Pharmacother. 2007 Jul;41(7):1174-80. doi: 10.1345/aph.1K045. Epub 2007 May 29. Ann Pharmacother. 2007. PMID: 17535842 Review.
The human information is inadequate to evaluate the risk of glipizide or the thiazolidinediones in pregnancy. In breast milk, 3 studies measured nonsignificant amounts of metformin and one study was unable to detect either glyburide or glipizide. ...Additional trial …
The human information is inadequate to evaluate the risk of glipizide or the thiazolidinediones in pregnancy. In breast milk, 3 studi …
Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.
Lebovitz HE. Lebovitz HE. Pharmacotherapy. 1985 Mar-Apr;5(2):63-77. doi: 10.1002/j.1875-9114.1985.tb03405.x. Pharmacotherapy. 1985. PMID: 3923454 Review.
Glipizide is a second-generation sulfonylurea in which the substitutions on the arylsulfonylurea nucleus are large, relatively nonpolar groups. ...The most important component of the antidiabetic action of glipizide is its effect in potentiating insulin action. G
Glipizide is a second-generation sulfonylurea in which the substitutions on the arylsulfonylurea nucleus are large, relatively nonpol
Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM.
Riddle MC, McDaniel PA, Tive LA. Riddle MC, et al. Diabetes Care. 1997 Jun;20(6):992-4. doi: 10.2337/diacare.20.6.992. Diabetes Care. 1997. PMID: 9167112 Clinical Trial.
OBJECTIVE: This study compared the effect of mild exercise while fasting on plasma glucose concentrations in subjects with NIDDM treated with extended-release glipizide and subjects not taking an oral hypoglycemic agent. RESEARCH DESIGN AND METHODS: Twenty-five moderately …
OBJECTIVE: This study compared the effect of mild exercise while fasting on plasma glucose concentrations in subjects with NIDDM treated wit …
Saxagliptin versus glipizide as add-on therapy to metformin: assessment of hypoglycemia.
Mintz ML, Minervini G. Mintz ML, et al. Curr Med Res Opin. 2014 May;30(5):761-70. doi: 10.1185/03007995.2014.880674. Epub 2014 Jan 30. Curr Med Res Opin. 2014. PMID: 24397584 Clinical Trial.
RESULTS: Of 858 patients randomized, 428 received saxagliptin + metformin, and 430 received glipizide + metformin. Saxagliptin was noninferior to glipizide in lowering HbA1c. ...Confirmed hypoglycemia, major events, and severe events occurred only with glipizide
RESULTS: Of 858 patients randomized, 428 received saxagliptin + metformin, and 430 received glipizide + metformin. Saxagliptin was no …
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, Kaufman KD, Goldstein BJ. Arjona Ferreira JC, et al. Diabetes Care. 2013 May;36(5):1067-73. doi: 10.2337/dc12-1365. Epub 2012 Dec 17. Diabetes Care. 2013. PMID: 23248197 Free PMC article. Clinical Trial.
There was a lower incidence of symptomatic hypoglycemia adverse events (AEs) with sitagliptin versus glipizide (6.2 and 17.0%, respectively; P = 0.001) and a decrease in body weight with sitagliptin (-0.6 kg) versus an increase (1.2 kg) with glipizide (difference, - …
There was a lower incidence of symptomatic hypoglycemia adverse events (AEs) with sitagliptin versus glipizide (6.2 and 17.0%, respec …
210 results